Back

Myosin activators for cardiomyopathy: all is not lost

1 September 2024 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: New treatment targets for personalised therapy in genetic cardiomyopathies Cardiomyopathies ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Zoltan Papp

University of Debrecen, Debrecen (Hungary)

4 More presentations in this session

Presentation thumbnail
Myosin inhibitors as novel drugs for hypertrophic cardiomyopathy
Professor J. van der Velden (Amsterdam, NL)
Slides Video
Presentation thumbnail
Targeting desmosomal adhesion to treat arrhythmogenic cardiomyopathy
Assistant Professor C. Schinner (Bern, CH)
Slides Video
Presentation thumbnail
Targeting titin in dilated cardiomyopathy
Professor W. Linke (Muenster, DE)
Slides Video
Presentation thumbnail
New treatment targets for personalised therapy in genetic cardiomyopathies - discussion
Video

Access the full session

Session thumbnail
New treatment targets for personalised therapy in genetic cardiomyopathies
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 13:45 CET
You may be interested in
thumbnail
Congress Presentation
Myotropic drugs
30 August 2024
thumbnail
Congress Presentation
The novel myosin activator, danicamtiv alters both systolic and diastolic functions in vitro and in vivo
12 May 2024
thumbnail
Congress Presentation
Danicamtiv, a Novel Cardiac Myosin Activator, Is Associated with Improved Right Ventricular Function: pre-clinical and clinical evidence in patients with DCM
30 August 2026
thumbnail
Congress Presentation
Myosin inhibitors in hypertrophic cardiomyopathy
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources